Mayor of Limerick, John Moran says the announcement of an additional US$1Billion (€927 Million) investment by Eli Lilly, further establishes Limerick as a key hub for innovation and life sciences.
This significant investment will create an additional 150 jobs at Lilly’s manufacturing facility in Raheen, bringing the total employment at the site to 450 by next summer.
It builds on last year’s similarly-sized commitment by Lilly, dedicated to the production of biologic active ingredients for Alzheimer's disease treatments.
The new investment marks the most ambitious manufacturing expansion in Lilly’s history.
Mayor Moran commented:
“We are thrilled that Lilly has chosen to deepen its commitment to Limerick. Their investment not only enhances our city’s reputation as a leader in the biopharma sector but also promises to make a tangible impact on global healthcare, especially in the treatment of Alzheimer’s disease.”
Mayor Moran added:
"The availability of a highly skilled talent pool in Limerick has made the region extremely attractive to major pharmaceutical companies like Eli Lilly, Regeneron, and Johnson & Johnson. The combination of local expertise, world-class educational institutions, and a welcoming and thriving business environment has positioned Limerick as a global biopharma hub. These investments are driving job creation and cementing the city’s reputation as a leader in cutting-edge healthcare solutions.”
Once complete, The Lilly facility in Raheen will join Lilly’s global manufacturing network producing the biologic active ingredients for the company’s Alzheimer’s disease portfolio and other biologic medicines.